Financial Performance - For the fiscal year ending December 31, 2025, the company reported revenue of RMB 130.27 million, representing a year-on-year increase of approximately 25% compared to RMB 104.70 million in 2024[4]. - The company incurred a net loss of RMB 1.79 billion for the fiscal year 2025, compared to a net loss of RMB 677.64 million in 2024[4]. - Cash and bank balances as of December 31, 2025, amounted to RMB 2.07 billion, a significant increase from RMB 394.92 million in 2024[4]. - The group's revenue for the year ended December 31, 2025, was RMB 130,267 thousand, representing an increase of 24.4% from RMB 104,703 thousand in 2024[77]. - The net loss for the year was RMB 1,794,528 thousand, compared to a net loss of RMB 677,641 thousand in 2024, reflecting a significant increase in losses[77]. - The adjusted net loss (non-IFRS measure) for the year ended December 31, 2025, was RMB 226.5 million, compared to RMB 249.7 million for the year ended December 31, 2024[68]. - The effective corporate tax rate for the company was 15% for the year, benefiting from its status as a "High-tech Enterprise" in China[93]. - The company reported a basic loss per share of RMB 6.07 for 2025, compared to RMB 2.62 for 2024, reflecting a worsening financial position[103]. Product Development and Clinical Trials - The company launched its first approved product, a KRAS G12C inhibitor, in 2024, which was included in the national medical insurance drug list in 2025[5]. - The company’s lead product, GFH375, entered the global first Phase III registration clinical trial for oral KRAS G12D inhibitors in November 2025, targeting metastatic pancreatic cancer[8]. - GFH375 demonstrated an overall response rate (ORR) of 57.7% and a disease control rate (DCR) of 88.5% in a study involving 26 evaluable NSCLC patients[11]. - The KROCUS study, combining Fluorouracil with Cetuximab, has shown an objective response rate (ORR) of 80% and a disease control rate (DCR) of 100% in 45 evaluable patients, with a median progression-free survival (mPFS) of 12.5 months[15]. - The company is developing a dual-target therapy for cachexia, which affects over 60% of pancreatic cancer patients, aiming to provide a new targeted treatment matrix for pancreatic cancer[14]. - The KROCUS study represents the world's first KRAS+EGFR first-line treatment for non-small cell lung cancer (NSCLC), which accounts for over 80% of lung cancer cases, with a mutation rate of nearly 30%[16]. - The company is advancing the first GDF15/IL-6 dual antibody therapy for cachexia, which is currently in I-phase clinical trials, targeting a significant unmet need in cancer and chronic disease patients[16]. - The oral STAT6 PROTAC degrader GFH946 is being developed to address the unmet needs in type 2 inflammatory diseases, showing superior in vitro activity compared to existing treatments[16]. - GFH375 is a small molecule oral KRAS G12D inhibitor, entering a Phase I/II clinical trial in China in June 2024 and a Phase III registration trial for metastatic pancreatic cancer in November 2025[21]. - The company has secured bank loans totaling RMB 83,901 thousand, with interest rates ranging from 2.25% to 2.75% for unsecured loans and 2.50% for secured loans[107][108]. Market Opportunities - The global market for KRAS inhibitors is expected to reach USD 7 billion by the end of 2025, with a peak sales forecast for RMC-6236 increasing from USD 230 million at the end of 2024 to USD 7 billion by the end of 2025[49]. - The KRAS G12D mutation accounts for approximately 30% of all KRAS mutations, with the market for KRAS G12D inhibitors projected to grow significantly, reaching USD 7.8 billion by 2034, with a CAGR of 35% over the next ten years[49]. - The global incidence of pancreatic cancer is expected to exceed 770,000 new cases by 2037, with a CAGR of 2.6% over the next ten years, indicating a significant market opportunity[52]. - The global pancreatic cancer drug market is projected to exceed RMB 93 billion by 2037, with a CAGR of 13.6% over the next decade[54]. Research and Development - The company has one of the most comprehensive RAS-targeted therapy matrices globally, including selective and pan-RAS inhibitors, with various molecular types such as small molecule inhibitors and antibody-drug conjugates[12]. - The pipeline includes various selective and pan-RAS inhibitors, as well as dual antibody therapies targeting cachexia, which are expected to bring new treatment options for pancreatic cancer[14]. - The company has obtained a total of 57 authorized patents by the end of 2025, covering Asia, Europe, and North America, which supports the uniqueness and technological advancement of its products[46]. - The company is developing a next-generation drug development platform, enhancing capabilities in target discovery, molecular optimization, and clinical development[45]. - The FAScon platform aims to expand from RAS pathway targeting to broader disease areas, exploring synergistic effects beyond molecular levels[45]. Corporate Governance and Management - The company completed its transition to a limited company and listed its H-shares on September 19, 2025, enhancing its corporate governance structure[111]. - Following a special resolution on February 9, 2026, the company abolished its supervisory board, transferring its powers to the audit committee, which reflects a shift in governance[117]. - Mr. Wu Dongcheng will resign as Co-Company Secretary effective March 24, 2026, with no disagreements with the board[119]. - Ms. Huang Meifeng has been appointed as Co-Company Secretary, Authorized Representative, and Legal Process Agent effective March 24, 2026[119]. - The company has received a new exemption from strict compliance with Listing Rules regarding Ms. Zhang's qualifications as Co-Company Secretary, effective March 24, 2026, until September 18, 2028[125]. Operational Efficiency - The company aims to reduce operational costs by 10% through improved efficiency measures implemented in Q2 2026[137]. - The company has achieved a disease control rate (DCR) of 70% in recent clinical trials, indicating strong efficacy of its leading product[135]. - The company is focusing on enhancing its intellectual property portfolio, with five new patents filed in the last quarter[136]. Strategic Partnerships and Collaborations - The company is actively pursuing international collaborations and partnerships to enhance product development and commercialization strategies, leveraging its diverse pipeline of small molecules and antibody-drug conjugates[55]. - The company’s collaboration partner, Verastem, exercised an option for GFH375 in January 2025, obtaining development and commercialization rights outside Greater China[10].
劲方医药-B(02595) - 2025 - 年度业绩